Clinical trial
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination…
NCT00002657 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00002657 |
|---|---|
| Title | SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant |
| Official title | Phase II Trial of Sequential Modification of Immunosuppression, Interferon Alpha, and Promace-Cytabom For Treatment of Post-Cardiac Transplant Lymphoproliferation. |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH Eastern Cooperative Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug, Procedure, Radiation |
| Interventions | bleomycin sulfate, recombinant interferon alfa, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide, methotrexate, prednisone, vincristine sulfate, conventional surgery and 1 more |
| Enrollment | 20 |
| Start date | May 1, 1995 |
| Primary completion | Nov 1, 2003 |
| Completion | Jul 1, 2011 |
| First posted | Jun 22, 2004 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: